WHO ICTRP trial
An exploratory clinical study of Camrelizumab combined with nab-paclitaxel…
ChiCTR2100048612 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2100048612 |
|---|---|
| Public title | An exploratory clinical study of Camrelizumab combined with nab-paclitaxel second-line and above in the treatment of small cell lung cancer |
| Scientific title | An exploratory clinical study of Camrelizumab combined with nab-paclitaxel second-line and above in the treatment of small cell lung cancer |
| Primary sponsor | the Affiliated Cancer Hospital of Harbin Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | small cell lung cancer |
| Interventions | Case series:camrelizumab combined with chemotherapy |
| Registration date | Jul 11, 2021 |
| Target size | Case series:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: